Skip to main content
VIVOZON PHARMACEUTICAL CO., LTD. logo

VIVOZON PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 082800 ISIN · KR7082800004 KO Manufacturing
Open in API
Filings indexed 590 across all filing types
Latest filing 2020-01-22 Regulatory Filings
Country KR South Korea
Listing KO 082800

About VIVOZON PHARMACEUTICAL CO., LTD.

https://www.vivozon.com/

VIVOZON PHARMACEUTICAL CO., LTD. is a research and development company specializing in the discovery and commercialization of innovative drugs, with a primary focus on pain and central nervous system (CNS) diseases. The company utilizes a multi-target drug development platform to create new chemical entities that act on multiple targets to achieve synergistic efficacy. This approach integrates efficacy-based screening from the early stages of discovery to identify candidate substances with a high potential for successful clinical development. Its lead pipeline candidate is Opiranserin (VVZ-149), a first-in-class, non-narcotic injectable analgesic for post-operative pain management. The company is actively expanding its pipeline to address a broader range of unmet medical needs within the CNS field.

Recent filings

Filing Released Lang Actions
불성실공시법인지정(공시번복)
Regulatory Filings Classification · 95% confidence The document is a formal regulatory notice regarding the designation of a company as an 'unfaithful disclosure corporation' (불성실공시법인) due to a disclosure reversal (공시번복). It details the penalty points, the regulatory basis (KOSDAQ market disclosure regulations), and the consequences of the designation. This fits the definition of a regulatory announcement regarding legal or compliance matters, which falls under the RNS (Regulatory Filings) category as it does not fit into specific categories like legal proceedings (LTR) or financial reports.
2020-01-22 Korean
주권매매거래정지(불성실공시법인 지정)
Regulatory Filings Classification · 95% confidence The document is a short, formal notice regarding the suspension of stock trading ('주권매매거래정지') for a specific company due to being designated as an unfaithful disclosure corporation. It cites specific exchange regulations and provides the duration of the suspension. Since it is a regulatory announcement regarding trading status and does not fit into specific categories like M&A or financial reports, it falls under the general regulatory filing category.
2020-01-22 Korean
대표이사변경
Board/Management Information Classification · 100% confidence The document is a formal announcement regarding a change in the company's representative director (CEO). It details the names of the outgoing and incoming directors, the reason for the change, the date of the board resolution, and the professional background of the new appointee. This falls directly under the category of board or management changes.
2020-01-21 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 100% confidence The document is a regulatory filing titled '사외이사의 선임ㆍ해임 또는 중도퇴임에 관한 신고' (Report on the Appointment, Dismissal, or Resignation of Outside Directors). It details the appointment of a new outside director, Lee Yoon-chul, following an extraordinary general meeting. This falls under the category of board management and changes in corporate governance structure.
2020-01-21 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea (DART system) used when an entity's shareholding in a listed company crosses a 5% threshold or changes significantly. This falls under the 'Major Shareholding Notification' category.
2020-01-21 Korean
주요사항보고서(타법인주식및출자증권양도결정)
M&A Activity Classification · 95% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Korean Financial Supervisory Service/Korea Exchange. It details a specific corporate action: the decision to sell shares in another company (타법인 주식 및 출자증권 양도결정). This type of regulatory filing, which discloses significant corporate events such as asset disposals or M&A-related activities, falls under the 'Regulatory Filings' (RNS) category as it is a mandatory disclosure of a material event.
2020-01-20 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.